CD163

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Neoplasm, Patient, CD163, JAK1, Therapy, Research, Survival, Cancer, CD86, TGF-B2, OTCQB, STAT1, APC, HR, CD14, TGFB2, Interferon gamma, Messenger, TME, DMG, Glioma, Vaccine

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.

Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress

Retrieved on: 
Friday, March 3, 2023
Patient, Macrophage, AMTI, CD163, European, Congress, ECCO, AMT, Regulatory T cell, SAN, Partnership, Gut, RA, Rheumatoid arthritis, Pharmaceutical industry, Safety

SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, which is also in development for the treatment of rheumatoid arthritis (RA). AMT presented the data in Poster P584 Efficacy, Safety, and Tolerability of AMT-101: A Gut Selective Oral IL-10 Fusion in the Phase 2 FILLMORE Trial of Patients with Chronic Pouchitis at the European Crohn’s and Colitis Organisation (ECCO) ’23 Congress.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients.
  • AMT presented the data in Poster P584 Efficacy, Safety, and Tolerability of AMT-101: A Gut Selective Oral IL-10 Fusion in the Phase 2 FILLMORE Trial of Patients with Chronic Pouchitis at the European Crohn’s and Colitis Organisation (ECCO) ’23 Congress.
  • “We are pleased to share these important new findings from the FILLMORE Phase 2 trial in patients with chronic pouchitis.
  • “These data further support advancement of once daily, oral AMT-101 for chronic pouchitis,” added Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT.

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022
Neoplasm, Retina, RO, PR, COVID-19, Pneumonitis, Liver, Tumor microenvironment, Health, Safety, Congress, Cancer, European Society for Medical Oncology, Protein engineering, ILT3, ILT2, GFRAL, Trae tha Truth, Biology, Therapy, LIR, Merck, LILRB4, ILT, RECIST, Translation, Oncology, Disease, Patient, ILT4, ESMO, Linearity, Cell, Failure, LAIR1, NGM, Myelocyte, G5, Merck Sharp & Dohme Federal Credit Union, Part, CD163, Merck & Co., Risk, Pharmaceutical industry, Vaccine

The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).

Key Points: 
  • The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).
  • The Phase 2 portion of the trial will include expansion cohorts of patients treated with NGM707 in combination with KEYTRUDA (Part 2b) in several advanced solid tumor types.
  • The Part 1a arm enrolled patients into escalating NGM707 dose cohorts (6 mg to 1800 mg) administered intravenously every three weeks.
  • As of a November 23, 2022 data cut-off, 34 patients have been enrolled in the monotherapy dose escalation.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Retrieved on: 
Monday, November 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Patient, Clinical trial, Plasma protein binding, Week, CD163, ORR, Lupus, EGFR, Dialysis, American College of Rheumatology, American College, DNA, UPCR, Kidney, Lupus nephritis, Death, Disease, Safety, Immune system, Degenerative disease, CRR, ACR, Inflammation, Skin manifestations of sarcoidosis, Chronic kidney disease, Immunosuppression, SLE, EOT, Biomarker, Diagnosis, Phase 1, Risk, Sec61, Proteinuria, Expressway Authority of Thailand, Pharmaceutical industry, Aluminium, Medical imaging, Synthetic oil, Medical device, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Paclitaxel, Review, Coronavirus, Society, SEC, TAM, Risk, NYSE, Drug discovery, Immunotherapy, Biopharmaceutical, Securities Exchange Act of 1934, Securities Act of 1933, Tumor-associated macrophage, CD86, Disease, SITC, Forward-looking statement, Abstract, NYSE American, Neoplasm, Convention center, History, CD163, Technetium-99m, Boston Convention and Exhibition Center, Investigational New Drug, Health, Decision-making, Phenotype, Toxicity, CD80, Wound healing, Research, Annual report, Macrophage, Pharmaceutical industry, Cancer

The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.

Key Points: 
  • The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.
  • These details were embargoed by SITC until the week of the meeting.
  • Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home .
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EOS, Patient, ORR, EOT, Immunosuppression, Private Securities Litigation Reform Act, DNA, Dialysis, Week, Lupus nephritis, Society, Association, Glomerular filtration rate, Death, Safety, Biomarker, CRR, SLE, Disease, Phase 1, EGFR, Nasdaq, Sec61, UPCR, Chronic kidney disease, Annual general meeting, ASN, CD163, U.S. Securities and Exchange Commission, Clinical trial, Autoimmune hepatitis, Forward-looking statement, Risk, Expressway Authority of Thailand, Inflammation, Degenerative disease, Proteinuria, Kidney, Plasma protein binding, Diagnosis, Treatment, Lupus, Pharmaceutical industry, Medical imaging, Synthetic oil, Dentistry, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

OncoResponse Presents Data on Multiple Immuno-oncology Agents at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

Retrieved on: 
Friday, November 12, 2021
SITC, Lung cancer, NSG, Neoplasm, MD Anderson Cancer Center, Clinical trial, Doctor of Philosophy, Alexandria Real Estate Equities, Cancer immunotherapy, Society, Tams, Immunotherapy, Tumor microenvironment, CPI, CD163, Twitter, Annual general meeting, Half-life, Antibody, LinkedIn, Therapy, Society for Immunotherapy of Cancer, TAM, Immunosuppression, IND, Qatar Investment Authority, Vaccine, Pharmaceutical industry

Data presented included preclinical findings on three monoclonal antibodies developed utilizing OncoResponse's proprietary B-cell platform that leverages data from elite responders to cancer immunotherapy in order to rapidly identify fully human therapeutic antibodies.

Key Points: 
  • Data presented included preclinical findings on three monoclonal antibodies developed utilizing OncoResponse's proprietary B-cell platform that leverages data from elite responders to cancer immunotherapy in order to rapidly identify fully human therapeutic antibodies.
  • "OncoResponse is focused on the development of human antibodies that modulate immune cell activity and enhance immunotherapy responses.
  • Our data presented at SITC highlight three investigational targets that provide initial and compelling data demonstrating immune activity and the ability to modulate the tumor microenvironment," said Kamal Puri, PhD, Chief Scientific Officer of OncoResponse.
  • OncoResponse, Inc. is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders.